Finvest
TEVA Pharmaceuticals · Generic drugs · Neuroscience · Turnaround · Thesis updated June 12, 2026

New drugs are carrying Teva through Revlimid

01 Running thesis

The turnaround has real proof now

Teva is trying to move from a low-growth generic drug company to a mix of generics, biosimilars, and higher-margin branded medicines. Q1 2026 helped that case. Revenue reached $4.0 billion, up 4% from Q1 2025, and non-GAAP EPS was $0.53. Both beat analyst expectations in the company materials.

The strongest sign came from the newer medicines. In Q1 2026, U.S. Austedo revenue rose 41% to $559 million, Ajovy rose 64% to $87 million, and Uzedy rose 62% to $63 million. That matters because Teva is losing a large stream of revenue from generic Revlimid, with management calling out about $1.1 billion of pressure in 2026.

The bull case is that Teva can use Austedo, Ajovy, Uzedy, biosimilars, and cost savings to keep growing while margins improve. Management still says it is on track for a 30% operating margin target by 2027. A completed TAPI sale could also bring in cash and speed debt reduction.

The bear case is that one strong quarter does not settle the year. If Austedo or the other growth drugs slow, the Revlimid decline could show up more clearly. The FTC review of inhaler patents and the stalled TAPI sale also keep the story from being clean.

Apr 2026▲Q1 2026 revenue was $4.0 billion, up 4%, and non-GAAP EPS was $0.53. Strong growth from Austedo, Ajovy, and Uzedy made the turnaround case more convincing.
Apr 2026▲The Q1 2026 filing showed U.S. Austedo revenue up 41%, Ajovy up 64%, and Uzedy up 62%. Teva also agreed to acquire Emalex Biosciences for $700 million.
Feb 2026→The 2025 Form 10-K confirmed strong U.S. growth and weak Europe and International results. It also added the FTC inhaler patent investigation as a clear risk.
Jan 2026▲Full-year 2025 results showed Austedo, Uzedy, and Ajovy growing strongly, while net debt to EBITDA improved to 2.5x. Management also quantified about $1.1 billion of 2026 pressure from generic Revlimid.
Nov 2025▼Exclusive talks to sell TAPI ended, delaying a key debt reduction catalyst. U.S. operations stayed strong, but the sale process became less certain.
Jul 2025▲Teva raised 2025 expectations for Austedo, Ajovy, and Uzedy by a combined $95 million. That helped offset a softer view for generics.
02 Business model

Generics scale meets branded drugs

Teva makes money by selling prescription medicines. A large part of the company is still generic drugs, which are lower-cost versions of branded drugs after exclusivity ends. This business benefits from manufacturing scale, global distribution, and a wide product list, but pricing can be tough.

The newer growth side is branded medicine. Austedo, Ajovy, and Uzedy have patent protection and stronger pricing power than many generics. That mix shift is central to Teva's Pivot to Growth plan.

Teva also sells biosimilars, which are close copies of complex biologic drugs, and it has a pipeline that includes olanzapine LAI, duvakitug, DARI, and ecopipam. These are options on future growth, but drug approvals and launches are never guaranteed.

The balance sheet still matters. Teva has made progress, with net debt to EBITDA at 2.5x after 2025, but it is still working toward a 2x goal. Selling TAPI, its active pharmaceutical ingredient business, would help, but the first exclusive talks ended and a new sale process is under way.

03 Product portfolio

The drugs that matter most

Growth engine

Austedo

Austedo is Teva's most important growth drug. U.S. revenue was $2.22 billion in 2025, up 35%, and Q1 2026 U.S. revenue rose 41% to $559 million.

Growth engine

Ajovy

Ajovy treats migraine prevention and is still growing from a smaller base. U.S. revenue was $295 million in 2025, up 42%, and Q1 2026 U.S. revenue rose 64% to $87 million.

Growth engine

Uzedy

Uzedy is a long-acting injectable schizophrenia medicine. U.S. revenue was $191 million in 2025, up 63%, and Q1 2026 U.S. revenue rose 62% to $63 million.

Cash cow

Global generics

Generics remain Teva's broad base business. The U.S. generics business grew 2% in 2025, while European generics declined 2% in local currency terms.

Option

Biosimilars

Biosimilars are a growth bridge between generics and branded drugs. Management has said the company is on track to grow this business significantly by 2027.

Option

Olanzapine LAI

Olanzapine LAI is a late-stage long-acting injectable medicine. Teva submitted the NDA in December 2025 and expects a possible approval and launch in late 2026.

Option

Duvakitug and ecopipam

Duvakitug is in a Phase 3 program with Sanofi, with Phase 2 maintenance data expected in H1 2026. Ecopipam came through the Emalex Biosciences deal and targets pediatric Tourette syndrome.

04 Business segments

U.S. growth carries the mix

United States53%growing fast
Europe29%declining
International Markets13%declining
Other Activities including TAPI5%declining

The segment mix uses full-year 2025 revenue from Teva's 2025 Form 10-K. The United States is the clear growth center, while Europe and International Markets were weaker in 2025.

05 Risk factors

What could break the setup

Revlimid cliff overwhelms growth

High impact · Medium odds

Teva faces about $1.1 billion of 2026 revenue pressure from lower generic Revlimid sales. Management expects this to be largely covered by newer medicines and the core business. If that math fails, revenue growth and margin targets get harder.

We watchTrack quarterly U.S. revenue for Austedo, Ajovy, Uzedy, and generic lenalidomide capsules.

Austedo slows

High impact · Medium odds

Austedo is the largest growth engine in the story. It produced $2.22 billion of U.S. revenue in 2025 and kept growing fast in Q1 2026. Any sharp slowdown would weaken confidence in the 2027 target and the peak sales case.

We watchWatch Austedo quarterly U.S. revenue growth and any updates tied to 2027 price negotiation effects.

TAPI sale slips again

Medium impact · Medium odds

Teva wants to sell TAPI, its active pharmaceutical ingredient business, to focus the company and help reduce debt. Exclusive talks with one buyer ended in 2025, and a renewed sale process began. A weak price or no deal would slow balance sheet repair.

We watchWatch for a signed TAPI sale agreement, sale price, and expected closing date.

FTC inhaler patent action

Medium impact · Medium odds

The FTC is investigating Teva's Orange Book patent listings for certain inhaler products. Orange Book listings can affect when generic rivals enter the market. An adverse result could mean legal costs, penalties, or faster generic competition.

We watchMonitor FTC statements, court filings, settlements, and any change in inhaler generic competition.

Pipeline and deal timing disappoints

Medium impact · Medium odds

The next phase of growth depends partly on new launches and late-stage assets. Olanzapine LAI has a possible late 2026 approval and launch, duvakitug data are expected in H1 2026, and Emalex adds ecopipam. Delays or weak data would lower future growth options.

We watchWatch olanzapine LAI approval timing, duvakitug maintenance data, Emalex closing, and ecopipam NDA timing.
06 Quick answers

In one breath

What does Teva Pharmaceutical do?

Teva sells prescription drugs around the world. It is best known for generic drugs, but its growth now depends more on branded medicines like Austedo, Ajovy, and Uzedy.

Why is Revlimid important for Teva?

Teva sells a generic version of Revlimid, called lenalidomide capsules. That revenue is falling in 2026, and management has pointed to about $1.1 billion of pressure from the decline.

What is the main bull case for TEVA stock?

The bull case is that Teva's newer branded medicines keep growing fast enough to cover the Revlimid decline. If that happens while debt falls and margins rise, the turnaround gets more credible.

What is the biggest risk for Teva?

The biggest near-term risk is that growth drugs do not fully cover the 2026 Revlimid headwind. The TAPI sale and the FTC inhaler patent probe are also important risks to watch.